Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma

NCT00512798 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

47

Enrollment

OTHER

Sponsor class

Stopped This study was terminated due to lack of efficacy

Conditions

Brain and Central Nervous System Tumors
Melanoma
Solid Tumor

Interventions

DRUG: PS-341 (VELCADE)
DRUG: temozolomide
OTHER: immunoenzyme technique
DRUG: PS-341 (VELCADE)
DRUG: Temozolomide

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators

[object Object]